DUBLIN–(BUSINESS WIRE)–The “Radiopharmaceuticals Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The global radiopharmaceuticals market reached a value of US$ 4.9 Billion in 2021. Looking forward, the market to reach US$ 7.2 Billion by 2027, exhibiting a CAGR of 6.62% during 2021-2027.
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Radiopharmaceuticals Market Trends:
The increasing prevalence of cancerous diseases on account of the rising aging population and unhealthy dietary patterns represent the key factors contributing to the growing use of radiopharmaceuticals across the globe. Apart from this, the escalating number of diagnostic centers is also supporting the market.
Moreover, the rising number of oncologists that are suggesting disease-targeted cancer therapy, which utilizes drugs to target specific proteins and genes involved in the development of cancer cells, are positively influencing the overall sales.
Furthermore, the use of radiolabeled peptides and monoclonal antibodies for the diagnosis and treatment of cancerous tumors, along with rising healthcare expenditures, is strengthening the market growth.
Other major factors anticipated to propel the growth of the market include the increasing use of radiopharmaceuticals by oncologists to track radioactivity throughout the body and determine the presence of cancer cells and the increasing shift towards positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) scans.
Key Questions Answered in This Report:
- How has the global radiopharmaceuticals market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global radiopharmaceuticals market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global radiopharmaceuticals market and who are the key players?
- What is the degree of competition in the industry?
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being
- Advanced Accelerator Applications (Novartis AG)
- Bayer AG
- Bracco S.p.A.
- Cardinal Health Inc.
- Curium Pharma
- General Electric Company
- IBA RadioPharma Solutions
- Jubilant Pharma Limited
- Lantheus Medical Imaging Inc
- Nordion Inc. (Sotera Health)
- NTP Radioisotopes SOC Ltd
- PharmaLogic Holdings Corp.
- Siemens AG
Key Market Segmentation:
Breakup by Product Type:
- Diagnostic Nuclear Medicine
- Therapeutic Nuclear Medicine
Breakup by Application:
- Oncology
- Cardiology
- Neurology
- Endocrinology
- Others
Breakup by End Use:
- Hospitals and Clinics
- Research Institutes
- Diagnostic Centers
Breakup by Region:
North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
For more information about this report visit https://www.researchandmarkets.com/r/52w3s3
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
